Researcher
Magali de Bruyn
- Disciplines:Endocrinology and metabolic diseases, Gastro-enterology and hepatology, Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Translational Research in GastroIntestinal Disorders (Division)
Member
From1 Jan 2017 → 31 Oct 2018 - Immunobiology (Rega Institute) (Lab)
Member
From1 Nov 2011 → 31 Dec 2016
Projects
1 - 1 of 1
- The role of matrix metalloproteinases in chronic inflammatory bowel diseases: new insights and applications.From3 Nov 2011 → 31 Dec 2016Funding: IWT personal funding - strategic basic research grants
Publications
1 - 10 of 25
- TREM-1, the ideal predictive biomarker for endoscopic healing in anti-TNF-treated Crohn's disease patients?(2019)
Authors: Bram Verstockt, Sare Verstockt, Isabelle Cleynen, Magali de Bruyn, Gert Van Assche, Séverine Vermeire, Marc Ferrante
Pages: 1531 - + - Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases(2018)
Authors: Erwin Dreesen, Bram Verstockt, Sumin Bian, Magali de Bruyn, Gert Van Assche, Marc Ferrante, Ann Gils, Séverine Vermeire
Pages: 1937 - + - Comparisons of gut microbiota profiles in wild-type and gelatinase B/matrix metalloproteinase-9-deficient mice in acute DSS-induced colitis(2018)
Authors: Magali de Bruyn, João Guedelha Sabino, Doris Vandeputte, Séverine Vermeire, Jeroen Raes, Ghislain Opdenakker
- Failure of MMP-9 Antagonists in IBD: Demonstrating the Importance of Molecular Biology and Well-Controlled Early Phase Studies(2018)
Authors: Magali de Bruyn, Marc Ferrante
Pages: 1011 - 1013 - Effect of vedolizumab (anti-alpha 4 beta 7-integrin) therapy on histological healing and mucosal gene expression in patients with UC(2018)
Authors: Ingrid Arijs, Gert De Hertogh, Bart Lemmens, Magali de Bruyn, Wiebe Vanhove, Isabelle Cleynen, Kathleen Machiels, Marc Ferrante, Frans Schuit, Gert Van Assche, et al.
Pages: 43 - 52 - Epithelial organoid cultures from patients with ulcerative colitis and Crohn's disease: a truly long-term model to study the molecular basis for inflammatory bowel disease?(2017)
Authors: Manuel Noben, Bram Verstockt, Magali de Bruyn, Gert Van Assche, Séverine Vermeire, Catherine Verfaillie, Marc Ferrante
Pages: 2193 - 2195 - Inhibition of gelatinase B/MMP-9 does not attenuate colitis in murine models of inflammatory bowel disease(2017)
Authors: Magali de Bruyn, Christine Breynaert, Ingrid Arijs, Gert De Hertogh, Karel Geboes, Gianluca Matteoli, Jo Van Damme, Marc Ferrante, Séverine Vermeire, Gert Van Assche, et al.
- INCREASED BASELINE TNF-DRIVEN PATHWAYS OBSERVED IN PATIENTS WITH CROHN'S DISEASE NOT RESPONDING TO INFLIXIMAB(2017)
Authors: Bram Verstockt, Ingrid Arijs, Magali de Bruyn, Sare Verstockt, Gert Van Assche, Christine Breynaert, Séverine Vermeire, Marc Ferrante
Pages: S767 - S767 - Specific members of the predominant gut microbiota predict pouchitis following colectomy and IPAA in UC(2017)
Authors: Kathleen Machiels, João Guedelha Sabino, Leen Vandermosten, Marie Joossens, Ingrid Arijs, Magali de Bruyn, Gert Van Assche, Marc Ferrante, Jan Verhaegen, Kristel Van Steen, et al.
Pages: 79 - 88 - NOD2 and bacterial recognition as therapeutic targets for Crohn's disease(2017)
Authors: Magali de Bruyn, Séverine Vermeire
Pages: 1123 - 1139